β-adrenergic stimuli and rotating suspension culture enhance conversion of human adipogenic mesenchymal stem cells into highly conductive cardiac progenitors.
Clinical trials using human adipogeneic mesenchymal stem cells (hAdMSC) for the treatment of cardiac diseases have shown improvement in cardiac function and were proven safe. However, hAdMSC do not convert efficiently into cardiomyocytes (CMs) or vasculature. Thus, reprogramming hAdMSC into myocyte progenitors may fare better in future investigations. To reprogram hAdMSC into electrically conductive cardiac progenitor cells, we pioneered a 3-step reprogramming strategy that uses proven MESP1/ETS2 transcription factors, β-adrenergic and hypoxic signaling induced in 3D cardio-spheres. In stage1, ETS2 and MESP1 activated Nkx2.5, Tbx5, Mef2C, dHAND and GATA4 during the conversion of hAdMSC into cardiac progenitor cells. Next, in stage 2, β2AR activation repositioned cardiac progenitors into de novo immature conductive cardiac cells, along with the appearance of RYR2, CAV2.1, CAV3.1, Nav1.5, SERCA2 and CX45 gene transcripts and displayed action potentials. In stage 3, electrical conduction was fostered by 3D cardio-spheres formed in a Synthecon®, Inc. rotating bioreactor induced the appearance of hypoxic genes: HIF1α/β, PCG1α/β and NOS2 which coincided with the robust activation of adult contractile genes including MLC2v, TNNT2 and TNNI3, ion channel genes and the appearance of hyperpolarization-activated and cyclic nucleotide-gated channels (HCN1-4). Conduction velocities doubled to ~200mm/s after hypoxia, and doubled yet again after dissociation of the 3D cell clusters to ~400mm/s. By comparison normal conduction velocities within working ventricular myocytes in the whole heart ranges from 0.5-1m/s. Epinephrine stimulation of stage-3 cardiac cells in patches resulted in an increase in amplitude of the electrical wave, indicative of conductive cardiac cells. Our efficient protocol converted hAdMSC into highly conductive cardiac progenitors, demonstrated the potential utilization of stage-3 cells for tissue engineering applications for cardiac repair.